Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 30-33

  Müller, Martin C ^a   Hördt, Tanja ^a   Paschka, Peter ^a   Merx, Kirsten ^a   La Rosée, Paul ^a   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL; Minimal residual disease; Real time quantitative polymerase chain reaction; RNA stabilization

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA;

BLOOD SAMPLING; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DNA SYNTHESIS; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; REVIEW; RNA DEGRADATION; RNA EXTRACTION; RNA STABILITY; STATISTICAL SIGNIFICANCE;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA STABILITY; RNA, NEOPLASM;

EID: 2642516188     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077557     Document Type: Review

References (14)

1. Neumaier M, Braun A, Wagener C: Fundamentals of quality assessment of molecular amplification methods in clinical diagnostics. International Federation of Clinical Chemistry Scientific Division Committee on Molecular Biology Techniques. Clin Chem 1998;44:12-26.
2. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-1936.
3. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62-66.
4. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16:1579-1583.
5. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, Konig H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-1694.
6. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon t/ara-C. Leukemia 2003;17:2392-2400.
7. Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, Hochhaus A: Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16:2395-2399.
8. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, Herdman C, Bankaitis-Davis D, Nicholls N, Trollinger D, Tryon V: Stabilization of mRNA expression in whole blood samples. Clin Chem 2002;48:1883-1890.
9. Melo JV, Yan XH, Diamond J, Lin F, Cross NC, Goldman JM: Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: The risk in misinterpreting negative results. Leukemia 1996;10:1217-1221.
10. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118-3122.
11. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-3367.
12. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-1832.
13. Cross NC, Feng L, Bungey J, Goldman JM: Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993;11(suppl 1):39-43.
14. Müller MC, Hördt T, Paschka P, Weisser A, Petzold A, Merx K, König H, Hehlmann R, Hochhaus A: The impact of preanalytical and analytical standardization for the detection of minimal residual disease in CML patients after therapy (abstract). Blood 2002;100:548a.